Hiroyuki Fukui

Prof. Hiroyuki Fukui

Department of Molecular Studies for Incurable Diseases, Tokushima University, Tokushima 770-0855, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2015 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
YNYuki Nariai
Yuki Nariai
SKShuhei Kato
Shuhei Kato
TNTomohiro Nakano
Tomohiro Nakano
TKTomoyo Kanayama
Tomoyo Kanayama
HFHiroyuki Fukui
Hiroyuki Fukui
Kujin contains antiallergic compounds that inhibit upregulation of histamine H1 receptor (H1R) and interleukin (IL)‐4 gene expression. However, the underlying mechanism remains unknown. We sought to identify a Kujin‐derived antiallergic compound and investigate its mechanism of action. The H1R and IL‐4 mRNA levels were determined by real‐time quantitative RT‐PCR. To investigate the effects of maackiain in vivo, toluene‐2,4‐diisocyanate (TDI)‐sensitized rats were used as a nasal hypersensitivity animal model. We identified (−)‐maackiain as the responsible component. Synthetic maackiain showed stereoselectivity for the suppression of IL‐4 gene expression but not for H1R gene expression, suggesting distinct target proteins for transcriptional signaling. (−)‐Maackiain inhibited of PKCδ translocation to the Golgi and phosphorylation of Tyr311 on PKCδ, which led to the suppression of H1R gene transcription. However, (−)‐maackiain did not show any antioxidant activity or inhibition of PKCδ enzymatic activity per se. Pretreatment with maackiain alleviated nasal symptoms and suppressed TDI‐induced upregulations of H1R and IL‐4 gene expressions in TDI‐sensitized rats. These data suggest that (−)‐maackiain is a novel antiallergic compound that alleviates nasal symptoms in TDI‐sensitized allergy model rats through the inhibition of H1R and IL‐4 gene expression. The molecular mechanism underlying its suppressive effect for H1R gene expression is mediated by the inhibition of PKCδ activation.

1 February 2013 in International Immunopharmacology
Verified
Journal Article
Closed access
MHMasashi Hattori
Masashi Hattori
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
YBYuko Baba
Yuko Baba
SOShohei Ono
Shohei Ono
TNTomohiro Nakano
Tomohiro Nakano
HFHiroyuki Fukui
Hiroyuki Fukui

3 December 2012 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
KMKohei Miyagi
Kohei Miyagi
TTTakuma Terao
Takuma Terao
NSNoriko Sakamoto
Noriko Sakamoto
YYYosuke Yamawaki
Yosuke Yamawaki
HFHiroyuki Fukui
Hiroyuki Fukui
Histamine H1 receptor (H1R) gene is up-regulated in patients with allergic rhinitis, and its expression level strongly correlates with the severity of symptoms. However, the mechanism underlying this remains unknown. Here we report the mechanism of H1R gene up-regulation. The luciferase assay revealed the existence of two promoter regions, A and B1. Two AP-1 and one Ets-1 bound to region A, while Ku86, Ku70, and PARP-1 bound to region B1. Ku86 was responsible for DNA binding and poly(ADP-ribosyl)ated in response to phorbol-12-myristate-13-acetate stimulation, inducing its dissociation from region B1 that is crucial for promoter activity. Knockdown of Ku86 gene enhanced up-regulation of H1R gene expression. Experiments using inhibitors for MEK and PARP-1 indicate that regions A and B1 are downstream regulatory elements of the PKCδ/ERK/PARP-1 signaling pathway. Data suggest a novel mechanism for the up-regulation of H1R gene expression.

8 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
TWTomoharu Wakugawa
Tomoharu Wakugawa
HSHisato Sadakata
Hisato Sadakata
SKSeiichiro Kamimura
Seiichiro Kamimura
MTMai Takemoto
Mai Takemoto
HFHiroyuki Fukui
Hiroyuki Fukui
H1-antihistamines antagonize histamine and prevent it from binding to the histamine H1 receptor (H1R). Some of them also act as inverse agonists, which are more potent than pure antagonists because they suppress the constitutive H1R activity. Bilastine is a non-sedative antihistamine which is one of the most satisfy the requirements for oral antihistamines. However, there is no information to show the inverse agonist activity of bilastine including inositol phosphates accumulation, and its inverse agonist activity is yet to be elucidated. Here we evaluated whether bilastine has inverse agonist activity or not. Intracellular calcium concentration was measured using Fluo-8. Inositol phosphates accumulation was assayed using [3H]myo-inositol. The H1R mRNA level was measured using real-time RT-PCR. At rest, Ca2+ oscillation was observed, indicating that H1R has intrinsic activity. Bilastine attenuated this fluorescence oscillation. Bilastine suppressed the increase in IPs formation in a dose-dependent manner and it was about 80% of the control level at the dose of 3 μM. Bilastine also suppressed histamine-induced increase in IPs formation to the control level. Furthermore, bilastine suppressed basal H1R gene expression in a dose-dependent manner. Data suggest that bilastine is an inverse agonist. Preseasonal prophylactic administration with bilastine could down-regulate basal H1R gene expression in the nasal mucosa and ameliorate the nasal symptoms during the peak pollen period.

Verified
Journal Article
Open access
PDF file
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
YMYuko Miyamoto
Yuko Miyamoto
TTTakuma Terao
Takuma Terao
HYHaruka Yoshida
Haruka Yoshida
WKWakana Kuroda
Wakana Kuroda
HFHiroyuki Fukui
Hiroyuki Fukui
Histamine H1 receptor (H1R) is one of the targets of histamine in the nervous system and the peripheral tissues. Protein kinase Cδ (PKCδ) signaling is involved in histamine-induced upregulation of H1R gene expression in HeLa cells. Histamine also upregulates H1R gene expression in U-373 MG cells. However, the molecular signaling of this upregulation is still unclear. Here, we investigated the molecular mechanism of histamine-induced H1R gene upregulation in U-373 MG cells. Histamine-induced H1R gene upregulation was inhibited by H1R antagonist d-chlorpheniramine, but not by ranitidine, ciproxifan, or JNJ77777120, and H2R, H3R, or H4R antagonists, respectively. Ro-31-8220 and Go6976 also suppressed this upregulation, however, the PKCδ selective inhibitor rottlerin and the PKCβ selective inhibitor Ly333531 did not. Time-course studies showed distinct kinetics of H1R gene upregulation in U-373 MG cells from that in HeLa cells. A promoter assay revealed that the promoter region responsible for H1R gene upregulation in U-373 MG cells was different from that of HeLa cells. These data suggest that the H1R-activated H1R gene expression signaling pathway in U-373 MG cells is different from that in HeLa cells, possibly by using different promoters. The involvement of PKCα also suggests that compounds that target PKCδ could work as peripheral type H1R-selective inhibitors without a sedative effect.

25 November 2016
Verified
Book Chapter
Closed access
PDF file
HFHiroyuki Fukui
Hiroyuki Fukui
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
HNHisao Nemoto
Hisao Nemoto
YKYoshiaki Kitamura
Yoshiaki Kitamura
YKYoshiki Kashiwada
Yoshiki Kashiwada
NTNoriaki Takeda
Noriaki Takeda